Total medical devices industry M&A deals in Q4 2019 worth $1.44bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 80.7% over the previous quarter and a drop of 83% when compared with the last four-quarter average of $8.43bn.
The US held a 16.3% share of the global medical devices industry M&A deal value that totalled $8.8bn in Q4 2019.
In terms of deal activity, the US recorded 41 deals during Q4 2019, marking a drop of 26.8% over the previous quarter and a drop of 21.2% over the last four-quarter average.
The US medical devices industry M&A deals in Q4 2019: Top deals
The top five medical devices industry M&A deals accounted for 91.3% of the overall value during Q4 2019.
The combined value of the top five medical devices M&A deals stood at $1.31bn, against the overall value of $1.44bn recorded for the month.
The top five medical devices industry deals of Q4 2019 tracked by GlobalData were:
1) Laborie Medical Technologies’ $525m acquisition of Clinical Innovations
3) Amneal Pharmaceuticals’ $221.34m acquisition of AvKare
5) Dare Bioscience’s acquisition of Keratin Biosciences for $101.5m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.